JP2024523438A - Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン - Google Patents
Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン Download PDFInfo
- Publication number
- JP2024523438A JP2024523438A JP2023578700A JP2023578700A JP2024523438A JP 2024523438 A JP2024523438 A JP 2024523438A JP 2023578700 A JP2023578700 A JP 2023578700A JP 2023578700 A JP2023578700 A JP 2023578700A JP 2024523438 A JP2024523438 A JP 2024523438A
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- seq
- sequence
- amino acid
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212781P | 2021-06-21 | 2021-06-21 | |
| US63/212,781 | 2021-06-21 | ||
| US202163257879P | 2021-10-20 | 2021-10-20 | |
| US63/257,879 | 2021-10-20 | ||
| PCT/EP2022/066764 WO2022268740A1 (en) | 2021-06-21 | 2022-06-20 | Combination dosage regime of cd137 and pd-l1 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523438A true JP2024523438A (ja) | 2024-06-28 |
| JP2024523438A5 JP2024523438A5 (cg-RX-API-DMAC10.html) | 2025-06-27 |
Family
ID=82358492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578700A Pending JP2024523438A (ja) | 2021-06-21 | 2022-06-20 | Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240262924A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4359435A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024523438A (cg-RX-API-DMAC10.html) |
| BR (1) | BR112023027006A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3223375A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL309319A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202315891A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022268740A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020018820A1 (en) * | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
| JP2020529438A (ja) * | 2017-08-04 | 2020-10-08 | ゲンマブ エー/エス | Pd−l1およびcd137に結合する結合物質ならびにその使用 |
| WO2021092056A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sàrl | Methods of treatment with antibodies against bcma and cd3 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| AU2010229705A1 (en) | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| IN2014CN03887A (cg-RX-API-DMAC10.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| CN106459165B (zh) | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| SMT201900702T1 (it) | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
-
2022
- 2022-06-20 BR BR112023027006A patent/BR112023027006A2/pt unknown
- 2022-06-20 TW TW111122920A patent/TW202315891A/zh unknown
- 2022-06-20 WO PCT/EP2022/066764 patent/WO2022268740A1/en not_active Ceased
- 2022-06-20 US US18/570,257 patent/US20240262924A1/en active Pending
- 2022-06-20 CA CA3223375A patent/CA3223375A1/en active Pending
- 2022-06-20 EP EP22735846.2A patent/EP4359435A1/en active Pending
- 2022-06-20 IL IL309319A patent/IL309319A/en unknown
- 2022-06-20 JP JP2023578700A patent/JP2024523438A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020529438A (ja) * | 2017-08-04 | 2020-10-08 | ゲンマブ エー/エス | Pd−l1およびcd137に結合する結合物質ならびにその使用 |
| WO2020018820A1 (en) * | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
| WO2021092056A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sàrl | Methods of treatment with antibodies against bcma and cd3 |
Non-Patent Citations (1)
| Title |
|---|
| J. IMMUNOTHER. CANCER, vol. 8, Suppl.3, JPN6026021272, 2020, pages 250 - 251, ISSN: 0005869218 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240262924A1 (en) | 2024-08-08 |
| BR112023027006A2 (pt) | 2024-03-12 |
| CA3223375A1 (en) | 2022-12-29 |
| IL309319A (en) | 2024-02-01 |
| EP4359435A1 (en) | 2024-05-01 |
| WO2022268740A9 (en) | 2024-03-07 |
| TW202315891A (zh) | 2023-04-16 |
| WO2022268740A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7836786B2 (ja) | Pd-l1およびcd137に結合する結合物質ならびにその使用 | |
| JP6925278B2 (ja) | 液性免疫応答の増強方法 | |
| JP6931329B2 (ja) | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 | |
| WO2019129261A1 (en) | Anti-tigit antibodies and their use as therapeutics and diagnostics | |
| JP2023178323A (ja) | メソテリン及びcd137結合分子 | |
| JP7809062B2 (ja) | 療法において使用するための抗体 | |
| TW201825511A (zh) | 表現免疫檢查點調節子的溶瘤病毒 | |
| JP2019517773A (ja) | 抗lag−3抗体 | |
| JP7338083B2 (ja) | 抗hK2キメラ抗原受容体(CAR) | |
| JP2024526835A (ja) | Cd8結合ポリペプチド及びその使用 | |
| CN113454111A (zh) | 抗体配制剂 | |
| US20240262924A1 (en) | Combination dosage regime of cd137 and pd-l1 binding agents | |
| US20260028402A1 (en) | Anti-cd100 antibody and use thereof | |
| CN118215678A (zh) | Cd137和pd-l1结合剂的组合剂量方案 | |
| HK40081753A (en) | Antibodies for use in therapy | |
| JP2026506893A (ja) | Btn3a活性化抗体と免役チェックポイント阻害剤の併用 | |
| EA050156B1 (ru) | Антитела для применения в терапии | |
| HK40010370A (en) | Tri-chain antibody, preparation method and use thereof | |
| HK40068325B (en) | Anti-hvem antibodies and use thereof | |
| HK40061281A (en) | Antibody formulation | |
| HK1228954A1 (en) | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260601 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260727 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260807 |